DOCS Stock Recent News

Start Time: 17:00 January 1, 0000 5:50 PM ET Doximity, Inc. (NYSE:DOCS ) Q1 2025 Earnings Conference Call August 08, 2024, 17:00 PM ET Company Participants Jeff Tangney - Co-founder and CEO Nate Gross - Co-founder and CSO Anna Bryson - CFO Perry Gold - VP of IR Conference Call Participants Brian Peterson - Raymond James Scott Berg - Needham & Company Stephanie Davis - Barclays Jared Hass - William Blair John Pinney - Canaccord Genuity Allen Lutz - Bank of America Elizabeth Anderson - Evercore ISI Jessica Tassan - Piper Sandler Michael Cherny - Leerink Partners Craig Hettenbach - Morgan Stanley Jenny Cao - Truist Securities Stan Berenshteyn - Wells Fargo Securities Jenny Shen - BTIG Operator Good day, everyone, and welcome to the Doximity Fiscal First Quarter 2025 Earnings Call. At this time, I would like to hand things over to Vice President of Investor Relations, Perry Gold.

Doximity (DOCS) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.19 per share a year ago.

Beyond analysts' top -and-bottom-line estimates for Doximity (DOCS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.

Doximity (DOCS) closed the most recent trading day at $28.66, moving +1.49% from the previous trading session.

The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ICLR, OGN and DOCS are set to gain the most.

Dr Martens PLC (LSE:DOCS) has published a bare trading update prior to a Thursday AGM. The classic British footwear company said that “trading since the start of this financial year has been in line with expectations and our guidance for (financial 2025) remains unchanged”.

Doximity (DOCS) closed the most recent trading day at $27.97, moving +0.5% from the previous trading session.

Dr Martens PLC (LSE:DOCS) stock market rating is on something of a knife edge with analysts at Barclay's keen for visibility over the boot maker's direct-to-consumer sales channel. A less than emphatic recent trading update leaves investors guessing in regards to the company's prospects for the rest of the year.

NEW YORK, June 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Doximity, Inc. (NYSE: DOCS) on behalf of long-term stockholders following a class action complaint that was filed against Doximity on April 17, 2024 with a Class Period from February 9, 2022 to April 1, 2024. Our investigation concerns whether the board of directors of Doximity have breached their fiduciary duties to the company.

NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE:DOCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.